Get the Stockscreener App
7.83
0.51%
-0.04
After Hours:
7.83
Amneal Pharmaceuticals Inc stock is traded at $7.83, with a volume of 1.30M.
It is down -0.51% in the last 24 hours and down -8.53% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$7.87
Open:
$7.92
24h Volume:
1.30M
Relative Volume:
1.22
Market Cap:
$2.43B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-11.51
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+1.29%
1M Performance:
-8.53%
6M Performance:
-3.81%
1Y Performance:
+36.65%
1-Day Range:
$7.735
$7.95
1-Week Range:
$7.66
$7.95
52-Week Range:
$5.01
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.83 | 2.43B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal gains FDA approval for dementia and oncology drugs - MSN
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amneal Launches Mesalamine and Receives FDA Approval for Lenalidomide - Pharmacy Practice News
AMRXAmneal Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide - Marketscreener.com
Amneal Pharmaceuticals Launching Mesalamine, Gets US FDA Approval for Lenalidomide - Marketscreener.com
Amneal introduces ulcerative colitis drug, plans future launch - Investing.com India
Amneal introduces ulcerative colitis drug, plans future launch By Investing.com - Investing.com Nigeria
Double Win for Amneal: Taps Into $147M Market Today, Secures Future Growth with New FDA Approval - StockTitan
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest - Yahoo Finance
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues - Simply Wall St
32,757 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Bought by Entropy Technologies LP - MarketBeat
Amneal Pharmaceuticals : Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months - Marketscreener.com
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 18.0% in January - MarketBeat
Stonebridge Financial Group LLC Buys Shares of 36,054 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake - Yahoo Finance
Amneal Pharmaceuticals Launches FOCINVEZ: A Game-Changer In Ready-To-Use Antiemetic Injectable Formulations... - WhaTech
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 80,000 Shares - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Consensus Target Price from Brokerages - MarketBeat
China Universal Asset Management Co. Ltd. Purchases Shares of 65,698 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row - Law360
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - MSN
Amneal Pharmaceuticals Director Sells 80,000 Shares - TradingView
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com Canada
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know - MSN
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Declines By 6.8% - MarketBeat
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Rising Allergy Prevalence Boosts Growth, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
SG Americas Securities LLC Has $590,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Says US FDA Accepts New-Drug Application for IPX203 to Treat Parkinson's Disease; Shares Rise - Marketscreener.com
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - BioSpace
Amneal Sets Key Q4 2024 Earnings DateMark Your Calendar for Major Pharma Update - StockTitan
Amneal Celebrates FDA Approvals For Generic Namzaric And Afinitor Disperz - News & Insights
Is Teva-Amneal Inhaler Case A Double-Edged Sword For The Generics Industry? - Citeline News & Insights
Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 5.2%Time to Buy? - MarketBeat
Premature Ejaculation Treatment Market to Grow by USD 1.53 Billion (2025-2029), Off-Label Drug Efficacy Boosts Revenue, Report with AI-Powered InsightsTechnavio - The Malaysian Reserve
Amneal Pharmaceuticals Gets FDA Approval for Alzheimer's Treatment and Brain Tumor Drug - MarketWatch
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - BioSpace
Amneal gains FDA approval for dementia and oncology drugs By Investing.com - Investing.com Australia
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Assenagon Asset Management S.A. Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Assenagon Asset Management S.A. Trims Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Hennessy Advisors Inc. Acquires 106,600 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars - Citeline News & Insights
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? - MSN
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):